Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Senecio | 1 | 2022 | 3 | 0.790 |
Why?
|
| Callilepis | 1 | 2022 | 3 | 0.790 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2022 | 69 | 0.530 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2022 | 21 | 0.380 |
Why?
|
| Biomarkers | 5 | 2022 | 327 | 0.370 |
Why?
|
| Metabolic Syndrome | 3 | 2020 | 64 | 0.350 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 27 | 0.350 |
Why?
|
| Vitamin D | 2 | 2021 | 41 | 0.350 |
Why?
|
| HIV Infections | 8 | 2024 | 5097 | 0.340 |
Why?
|
| Psoriasis | 2 | 2019 | 10 | 0.330 |
Why?
|
| Adult | 18 | 2022 | 5913 | 0.310 |
Why?
|
| Humans | 25 | 2024 | 14537 | 0.310 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2022 | 18 | 0.310 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 237 | 0.270 |
Why?
|
| Female | 18 | 2021 | 9103 | 0.260 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2022 | 5 | 0.260 |
Why?
|
| Middle Aged | 13 | 2020 | 3601 | 0.250 |
Why?
|
| Herbal Medicine | 1 | 2005 | 1 | 0.250 |
Why?
|
| Drug Contamination | 1 | 2005 | 3 | 0.240 |
Why?
|
| Medicine, African Traditional | 1 | 2005 | 25 | 0.240 |
Why?
|
| Menopause | 2 | 2015 | 24 | 0.240 |
Why?
|
| Vitamins | 2 | 2021 | 23 | 0.230 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 13 | 0.230 |
Why?
|
| Body Composition | 2 | 2015 | 153 | 0.230 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 1422 | 0.220 |
Why?
|
| Male | 13 | 2020 | 6754 | 0.210 |
Why?
|
| Anemia | 1 | 2022 | 41 | 0.200 |
Why?
|
| Kidney | 1 | 2022 | 46 | 0.200 |
Why?
|
| Adonis | 1 | 2022 | 2 | 0.200 |
Why?
|
| Solid Phase Extraction | 1 | 2022 | 3 | 0.200 |
Why?
|
| Capsaicin | 1 | 2001 | 1 | 0.200 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 7 | 0.200 |
Why?
|
| Medicine, Traditional | 1 | 2001 | 7 | 0.200 |
Why?
|
| Occult Blood | 1 | 2001 | 1 | 0.200 |
Why?
|
| Clinical Chemistry Tests | 1 | 2001 | 1 | 0.200 |
Why?
|
| Lycopersicon esculentum | 1 | 2001 | 2 | 0.200 |
Why?
|
| Plant Extracts | 1 | 2022 | 32 | 0.190 |
Why?
|
| Oxygenators | 1 | 2020 | 2 | 0.180 |
Why?
|
| Amino Acids, Aromatic | 1 | 2020 | 3 | 0.180 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2020 | 4 | 0.180 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hepcidins | 1 | 2020 | 6 | 0.180 |
Why?
|
| Kynurenine | 1 | 2020 | 7 | 0.180 |
Why?
|
| Tryptophan | 1 | 2020 | 8 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2020 | 27 | 0.180 |
Why?
|
| South Africa | 12 | 2022 | 7596 | 0.180 |
Why?
|
| Cushing Syndrome | 1 | 2020 | 3 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 150 | 0.170 |
Why?
|
| Treatment Failure | 1 | 2020 | 175 | 0.170 |
Why?
|
| Intra-Abdominal Fat | 1 | 2019 | 15 | 0.170 |
Why?
|
| Adipokines | 1 | 2019 | 11 | 0.170 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 92 | 0.170 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 30 | 0.160 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 55 | 0.160 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2019 | 118 | 0.160 |
Why?
|
| Pregnancy | 2 | 2021 | 1862 | 0.150 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 4 | 0.150 |
Why?
|
| Adiposity | 2 | 2015 | 96 | 0.140 |
Why?
|
| Insulin Resistance | 2 | 2019 | 79 | 0.140 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2020 | 324 | 0.140 |
Why?
|
| Obesity | 3 | 2015 | 367 | 0.140 |
Why?
|
| Parathyroid Hormone | 1 | 2015 | 13 | 0.130 |
Why?
|
| Thinness | 1 | 2015 | 18 | 0.130 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 19 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 472 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 3 | 2022 | 62 | 0.120 |
Why?
|
| Ovary | 1 | 2014 | 5 | 0.120 |
Why?
|
| Reproduction | 1 | 2014 | 25 | 0.120 |
Why?
|
| Aging | 1 | 2014 | 109 | 0.110 |
Why?
|
| Ferritins | 2 | 2024 | 23 | 0.110 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2013 | 27 | 0.110 |
Why?
|
| Potassium | 1 | 2013 | 25 | 0.110 |
Why?
|
| Sodium | 1 | 2013 | 30 | 0.100 |
Why?
|
| Urban Population | 1 | 2014 | 257 | 0.100 |
Why?
|
| Risk Factors | 4 | 2020 | 1475 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2017 | 543 | 0.100 |
Why?
|
| Creatinine | 2 | 2022 | 53 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2024 | 96 | 0.100 |
Why?
|
| Prognosis | 2 | 2024 | 199 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2013 | 317 | 0.090 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 1324 | 0.090 |
Why?
|
| Logistic Models | 2 | 2020 | 254 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2024 | 799 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2022 | 967 | 0.070 |
Why?
|
| Prevalence | 3 | 2018 | 1192 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2019 | 480 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2019 | 1160 | 0.070 |
Why?
|
| Age Factors | 2 | 2019 | 370 | 0.070 |
Why?
|
| Absorptiometry, Photon | 2 | 2015 | 85 | 0.060 |
Why?
|
| Trimethadione | 1 | 2005 | 1 | 0.060 |
Why?
|
| Propofol | 1 | 2005 | 1 | 0.060 |
Why?
|
| Solutions | 1 | 2005 | 2 | 0.060 |
Why?
|
| Acidosis, Lactic | 1 | 2005 | 5 | 0.060 |
Why?
|
| Diclofenac | 1 | 2005 | 10 | 0.060 |
Why?
|
| Uterine Rupture | 1 | 2005 | 3 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2005 | 18 | 0.060 |
Why?
|
| Seizures | 1 | 2005 | 20 | 0.060 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2005 | 12 | 0.060 |
Why?
|
| Infant | 2 | 2019 | 2244 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2024 | 9 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 5 | 0.060 |
Why?
|
| Aged | 2 | 2019 | 1740 | 0.060 |
Why?
|
| Alcoholic Intoxication | 1 | 2004 | 3 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2024 | 51 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2004 | 26 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 51 | 0.060 |
Why?
|
| Cytokines | 1 | 2024 | 107 | 0.050 |
Why?
|
| Multiple Trauma | 1 | 2002 | 4 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2022 | 6 | 0.050 |
Why?
|
| HIV Seroprevalence | 1 | 2002 | 15 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2022 | 19 | 0.050 |
Why?
|
| Iron | 1 | 2022 | 32 | 0.050 |
Why?
|
| Cystatin C | 1 | 2022 | 9 | 0.050 |
Why?
|
| Malawi | 1 | 2022 | 87 | 0.050 |
Why?
|
| Urban Health | 1 | 2002 | 78 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 179 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2001 | 21 | 0.050 |
Why?
|
| Uganda | 1 | 2022 | 197 | 0.050 |
Why?
|
| Guaiac | 1 | 2001 | 1 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2001 | 17 | 0.050 |
Why?
|
| Body Size | 1 | 2021 | 15 | 0.050 |
Why?
|
| Iohexol | 1 | 2021 | 7 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2021 | 14 | 0.050 |
Why?
|
| Gestational Age | 1 | 2021 | 80 | 0.050 |
Why?
|
| Equipment Reuse | 1 | 2020 | 2 | 0.050 |
Why?
|
| Blood Physiological Phenomena | 1 | 2020 | 3 | 0.050 |
Why?
|
| Equipment Design | 1 | 2020 | 27 | 0.050 |
Why?
|
| Oxygen | 1 | 2020 | 25 | 0.050 |
Why?
|
| Diet | 1 | 2001 | 109 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 51 | 0.040 |
Why?
|
| Models, Biological | 1 | 2020 | 77 | 0.040 |
Why?
|
| Skin Lightening Preparations | 1 | 2020 | 2 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 13 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 91 | 0.040 |
Why?
|
| Critical Illness | 1 | 2020 | 44 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2020 | 107 | 0.040 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 45 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2005 | 1748 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2019 | 64 | 0.040 |
Why?
|
| Lopinavir | 1 | 2020 | 137 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 217 | 0.040 |
Why?
|
| Ritonavir | 1 | 2020 | 137 | 0.040 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 2 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 38 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 171 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 376 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 198 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2019 | 40 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 385 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2019 | 120 | 0.040 |
Why?
|
| Alkynes | 1 | 2019 | 117 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 188 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 123 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 227 | 0.040 |
Why?
|
| Seasons | 1 | 2019 | 154 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 225 | 0.040 |
Why?
|
| Benzoxazines | 1 | 2019 | 123 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 253 | 0.040 |
Why?
|
| Nevirapine | 1 | 2019 | 146 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2019 | 120 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 260 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2020 | 278 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 685 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 167 | 0.040 |
Why?
|
| HIV | 1 | 2019 | 380 | 0.030 |
Why?
|
| Viral Load | 1 | 2020 | 819 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 18 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 26 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2015 | 6 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2014 | 11 | 0.030 |
Why?
|
| Estradiol | 1 | 2014 | 18 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 1479 | 0.030 |
Why?
|
| Bone Density | 1 | 2015 | 107 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 370 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2498 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2015 | 353 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2013 | 60 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 321 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 31 | 0.030 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2013 | 27 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 472 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 563 | 0.030 |
Why?
|
| Adolescent | 2 | 2004 | 2985 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2004 | 5 | 0.010 |
Why?
|
| Marijuana Smoking | 1 | 2004 | 2 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2004 | 23 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2002 | 16 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 107 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2002 | 109 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2002 | 325 | 0.010 |
Why?
|
| Child | 1 | 2002 | 2242 | 0.010 |
Why?
|